NRX Pharmaceuticals (NRXP) Total Liabilities (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Total Liabilities data on file, last reported at $25.7 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 21.47% year-over-year to $25.7 million in Q1 2026; TTM through Mar 2026 was $25.7 million, a 21.47% decrease from a year earlier, with the FY2025 full-year figure at $28.9 million, up 7.51% from the prior year.
• Total Liabilities for Q1 2026 stood at $25.7 million, down from $28.9 million in the prior quarter.
• Over the last five years, Total Liabilities for NRXP reached as high as $40.8 million in Q3 2025 and fell as low as $7.1 million in Q2 2022.
• Historically, Total Liabilities has averaged $22.9 million across 5 years, with a median of $22.6 million in 2023.
• Across the five-year window, Total Liabilities sank 87.86% in 2022 and soared 219.4% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $18.4 million in 2022, then increased by 3.48% to $19.0 million in 2023, then jumped by 41.09% to $26.9 million in 2024, then gained by 7.51% to $28.9 million in 2025, then dropped by 10.99% to $25.7 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $25.7 million in Q1 2026, $28.9 million in Q4 2025, and $40.8 million in Q3 2025.